113 related articles for article (PubMed ID: 21985997)
21. Efficacy and tolerability of intravenous paricalcitol in calcitriol-resistant hemodialysis patients with secondary hyperparathyroidism: 12-month prospective study.
Tonbul HZ; Solak Y; Atalay H; Turkmen K; Altintepe L
Ren Fail; 2012; 34(3):297-303. PubMed ID: 22251408
[TBL] [Abstract][Full Text] [Related]
22. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
23. Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determinations to evaluate bone turnover in patients with chronic renal failure.
López Gavilanes E; González Parra E; de la Piedra C; Caramelo C; Rapado A
Miner Electrolyte Metab; 1994; 20(5):259-64. PubMed ID: 7700213
[TBL] [Abstract][Full Text] [Related]
24. Oral calcitriol versus oral alfacalcidol for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: a randomized, crossover trial.
Moe S; Wazny LD; Martin JE
Can J Clin Pharmacol; 2008; 15(1):e36-43. PubMed ID: 18192704
[TBL] [Abstract][Full Text] [Related]
25. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism.
Akizawa T; Ohashi Y; Akiba T; Suzuki M; Nishizawa Y; Ogata E; Slatopolsky E; Kurokawa K
Ther Apher Dial; 2004 Dec; 8(6):480-91. PubMed ID: 15663548
[TBL] [Abstract][Full Text] [Related]
26. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism.
Park CW; Oh YS; Shin YS; Kim CM; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
Am J Kidney Dis; 1999 Jan; 33(1):73-81. PubMed ID: 9915270
[TBL] [Abstract][Full Text] [Related]
27. Effect of Cinacalcet Combined with Calcitriol on the Clinical Outcome and Bone Metabolism in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism.
Yuan F; Chen X; Wang C; Li Z; Liu H
Blood Purif; 2018; 45(1-3):73-78. PubMed ID: 29216631
[TBL] [Abstract][Full Text] [Related]
28. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
29. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.
Vlassopoulos D; Noussias C; Revenas K; Hadjilouka-Mantaka A; Arvanitis D; Tzortzis G; Hadjiconstantinou V
Ren Fail; 1999 Mar; 21(2):199-207. PubMed ID: 10088180
[TBL] [Abstract][Full Text] [Related]
30. Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
Liou HH; Chiang SS; Tsai SC; Chang CC; Wu SC; Shieh SD; Huang TP
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Jun; 53(6):319-24. PubMed ID: 8087705
[TBL] [Abstract][Full Text] [Related]
31. Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage.
Grekas D; Balaskas E; Kampouris H; Benos A; Konstantinou A; Sioullis A; Tourkantonis A
Clin Nephrol; 1999 Sep; 52(3):167-71. PubMed ID: 10499312
[TBL] [Abstract][Full Text] [Related]
32. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis.
Kim HW; Park CW; Shin YS; Kim YS; Shin SJ; Kim YS; Choi EJ; Chang YS; Bang BK
Nephron Clin Pract; 2006; 102(1):c21-9. PubMed ID: 16166802
[TBL] [Abstract][Full Text] [Related]
33. Prospective comparison of the effects of maxacalcitol and calcitriol in chronic hemodialysis patients with secondary hyperparathyroidism: a multicenter, randomized crossover study.
Mochizuki T; Naganuma S; Tanaka Y; Iwamoto Y; Ishiguro C; Kawashima Y; Maekawa K; Suda A; Akiba T;
Clin Nephrol; 2007 Jan; 67(1):12-9. PubMed ID: 17269594
[TBL] [Abstract][Full Text] [Related]
34. Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease.
Chen H; Cui Y; Xing C; Purrunsing Y; Zha X; Shen C; Zeng M; Yang G; Yu X; Zhang L; Jiang Y; Shen Z; Ma H; Yin C; Li Y; Wang N
Int Urol Nephrol; 2018 Dec; 50(12):2279-2288. PubMed ID: 30361964
[TBL] [Abstract][Full Text] [Related]
35. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
[TBL] [Abstract][Full Text] [Related]
36. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
37. Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.
Ross EA; Tian J; Abboud H; Hippensteel R; Melnick JZ; Pradhan RS; Williams LA; Hamm LL; Sprague SM
Am J Nephrol; 2008; 28(1):97-106. PubMed ID: 17914251
[TBL] [Abstract][Full Text] [Related]
38. Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients.
Doi S; Yorioka N; Usui K; Shigemoto K; Harada S
Intern Med; 2003 Oct; 42(10):955-9. PubMed ID: 14606707
[TBL] [Abstract][Full Text] [Related]
39. Effect of CAPD and hemodialysis on parathyroid function.
Malberti F; Corradi B; Imbasciati E
Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
[TBL] [Abstract][Full Text] [Related]
40. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
